IPSC
NASDAQCentury Therapeutics Inc.
Price$2.41+0.06 (+2.34%)
01:30 PM07:45 PM
News · 26 weeks72+70%
2025-12-282026-06-21
Mix3690d
- Insider17(47%)
- SEC Filings10(28%)
- Other7(19%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- SECCentury Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDEROfficer Russotti Gregory sold $5,767 worth of shares (2,584 units at $2.23), decreasing direct ownership by 0.50% to 512,319 units (SEC Form 4) (for tax liability)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSVP Finance & Operations Carr Douglas sold $3,692 worth of shares (1,654 units at $2.23), decreasing direct ownership by 0.33% to 505,094 units (SEC Form 4) (tax liability)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 13,849 shares, decreasing direct ownership by 0.38% to 3,665,474 units (SEC Form 4) (withholding tax)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERChief Scientific Officer Cowan Chad covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.03% to 1,175,322 units (SEC Form 4) to satisfy withholding tax4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Director Riva Alessandro4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Director Quimi Daphne4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Director Murphy Martin Patrick4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Director Lee Han Myung4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Director Blackwell Kimberly4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDEROfficer Russotti Gregory sold $1,106 worth of shares (524 units at $2.11), decreasing direct ownership by 0.10% to 514,903 units (SEC Form 4) (withholding tax)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSVP Finance & Operations Carr Douglas sold $526 worth of shares (249 units at $2.11), decreasing direct ownership by 0.05% to 506,748 units (SEC Form 4) (withholding obligation)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 463 shares, decreasing direct ownership by 0.01% to 3,679,323 units (SEC Form 4) (withholding obligation)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- PRNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026Advancing CNTY-813 as a potential functional cure in Type 1 DiabetesCNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical modelsAllo-Evasion™ 5.0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse model without immunosuppressionPhase 1 clinical manufacturing process has been established demonstrating consistent endocrine purity and optimal islet cell contentCNTY-813 IND submission on track for 4Q 2026; initial clinical data expected in 2H 2027 PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC
- PRA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc. (NASDAQ:GTBP) recently put its third drug into the clinic — and the entire company has at times been valued at a small fraction of that. The gap between what the company is doing in the lab and what the market is paying for it is the whole story here, and a milestone reached in mid-May has brought it into sharp focus.
- ANALYSTMizuho initiated coverage on Century Therapeutics with a new price targetMizuho initiated coverage of Century Therapeutics with a rating of Outperform and set a new price target of $8.00
- SECSEC Form 424B7 filed by Century Therapeutics Inc.424B7 - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 31,172 shares, decreasing direct ownership by 0.84% to 3,679,786 units (SEC Form 4) to satisfy withholding tax4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Century Therapeutics Inc.SCHEDULE 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
- SECSEC Form SCHEDULE 13G filed by Century Therapeutics Inc.SCHEDULE 13G - Century Therapeutics, Inc. (0001850119) (Subject)
- PRCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsNORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company's Board of Directors. "Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs," said Rachelle Jacques, Chair of the Corbus Board of Directors. "His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Bre
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form 10-Q filed by Century Therapeutics Inc.10-Q - Century Therapeutics, Inc. (0001850119) (Filer)
IPSC FAQ
7 questionsWhat does Century Therapeutics Inc. do?
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and...Where does IPSC stock trade?
Century Therapeutics Inc. (IPSC) is listed on NASDAQ.What sector and industry is IPSC in?
Century Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Century Therapeutics Inc. go public?
Century Therapeutics Inc. (IPSC) completed its IPO in 2021.What are analysts saying about IPSC?
Century Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Mizuho: Outperform with a $800.00 price target on 2026-05-27.What companies are similar to IPSC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IPSC side-by-side with any of them on Quantisnow.How can I track IPSC on Quantisnow?
Quantisnow aggregates Century Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IPSC to receive live email and push alerts on every new disclosure.